Ceprotin (human protein C)
- Region
- 🇪🇺 EU
- Active substance
- human protein C
- Company
- Takeda Manufacturing Austria AG
- Status
- Authorised
- Therapeutic area
- Purpura Fulminans; Protein C Deficiency
- EU approval
- Mon 16 Jul 2001
- Application
- EMEA/H/C/000334
- ATC
- B01AD12
- Official record
- www.ema.europa.eu
Indication
CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein C deficiency.
Regulatory milestones
No milestones recorded in the last year.
Follow Ceprotin
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.